Unlock stock picks and a broker-level newsfeed that powers Wall Street.

ASX Penny Stocks To Consider In December 2024

In This Article:

As the Australian market braces for a slower start to Week 51, with the ASX 200 expected to open lower amid concerns over rate cuts and shifts in China's economic strategy, investors are keenly observing how these factors might influence their portfolios. Penny stocks, despite being an old term, continue to capture attention as they often represent smaller or newer companies with potential for growth at attractive price points. When these stocks are backed by strong financials and sound fundamentals, they can offer opportunities that may appeal to those looking for hidden value in quality investments.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.755

A$138.53M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.55

A$64.47M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.505

A$313.17M

★★★★★☆

SHAPE Australia (ASX:SHA)

A$2.80

A$232.15M

★★★★★★

Helloworld Travel (ASX:HLO)

A$1.935

A$315.05M

★★★★★★

MaxiPARTS (ASX:MXI)

A$1.75

A$96.8M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.60

A$784.13M

★★★★★☆

SKS Technologies Group (ASX:SKS)

A$1.59

A$215.17M

★★★★★★

Vita Life Sciences (ASX:VLS)

A$1.84

A$103.2M

★★★★★★

Servcorp (ASX:SRV)

A$4.86

A$479.51M

★★★★☆☆

Click here to see the full list of 1,049 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

CleanSpace Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: CleanSpace Holdings Limited designs, manufactures, and sells respiratory protection products and services for healthcare and industrial markets globally, with a market cap of A$30.80 million.

Operations: The company generates revenue of A$15.72 million from its respiratory products segment.

Market Cap: A$30.8M

CleanSpace Holdings, with a market cap of A$30.80 million, is navigating challenges typical of penny stocks. Despite generating A$15.72 million in revenue from its respiratory products, the company remains unprofitable and has seen losses increase at a significant rate over the past five years. However, it holds more cash than debt and has reduced its debt-to-equity ratio substantially over time. The company's short-term assets exceed both short-term and long-term liabilities, providing some financial stability. Nonetheless, volatility remains high and management's inexperience could affect strategic direction as they work towards profitability.

ASX:CSX Financial Position Analysis as at Dec 2024
ASX:CSX Financial Position Analysis as at Dec 2024

MaxiPARTS

Simply Wall St Financial Health Rating: ★★★★★★